Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 3/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 12/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31149207 | 0.88 | L3MBTL1 (0.52) | APLNRTAS2R14L3MBTL1KCNA5 | |
| SCHEMBL31149228 | 0.88 | APLNR (0.51) | APLNRTAS2R14L3MBTL1KCNA5PTGES | |
| SCHEMBL4183685 | 0.88 | L3MBTL1 (0.52) | APLNRTAS2R14L3MBTL1KCNA5 | |
| SCHEMBL31149689 | 0.88 | APLNR (0.51) | APLNRTAS2R14L3MBTL1KCNA5PTGES | |
| SCHEMBL31149661 | 0.88 | TAS2R14 (0.54) | APLNRTAS2R14L3MBTL1KCNA5PTGES | |
| SCHEMBL25578370 | 0.87 | TAS2R14 (0.55) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL25578283 | 0.84 | APLNR (0.52) | APLNRTAS2R14L3MBTL1PTGESTAS2R8 | |
| SCHEMBL30219708 | 0.84 | APLNR (0.52) | APLNRTAS2R14L3MBTL1PTGESTAS2R8 | |
| SCHEMBL31149206 | 0.83 | TAS2R14 (0.57) | APLNRTAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL31149813 | 0.83 | TAS2R14 (0.66) | TAS2R14PTGESTAS2R8CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| CN-115996924-B | Substituted pyrazolyl compounds and methods of use thereof | 诺华医药股份公司 | 2025-03-07 | — | — | CN | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024212024-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| CN-115996924-A | Substituted pyrazolyl compounds and methods of use thereof | 奇努克医疗加拿大公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4153586-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | Chinook Therapeutics Canada, Inc. (CA) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153585-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | Chinook Therapeutics Canada, Inc. (CA) | 2023-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | LDHA, LDHB, XDH | APLNR 4775/4885TAS2R14 3827/4885L3MBTL1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.